Outcomes of PCI Before, During, or After TAVR With Edwards’ Sapien 3 Platform Analyzed in TVT Registry Data

May 3, 2024—An analysis including 49,344 patients with stable coronary artery disease (CAD) showed that percutaneous coronary intervention (PCI) can be safely performed before, during, or after transcatheter aortic valve replacement (TAVR) in these patients.

The patients in the analysis were treated with PCI before (84.7%), after (1.3%), or simultaneously (14%) with TAVR using the Sapien 3 (Edwards Lifesciences) platform balloon-expandable bioprosthesis. The analysis was conducted using the TVT Registry and Medicare linkage between 2015 and 2024.

The results from the analysis were presented at SCAI 2024, the Society for Cardiovascular Angiography & Interventions scientific sessions held May 2-4 in Long Beach, California. The study abstract by Abhijeet Dhoble, MD, in available online in JSCAI.

The SCAI press release stated that the propensity-matched analysis showed the composite of all-cause mortality and stroke were similar in the three groups at 3 years of follow-up. The investigators noted that because of the small numbers of patients undergoing PCIs after the TAVR, PCI performed before TAVR had a slight advantage over concomitant PCI with TAVR at 3 years (P = .012).

“These findings are exciting as they slightly differ from previously published registry data,” commented Dr. Dhoble in the SCAI press release. “We believe this data will instill confidence and provide supporting evidence for many physicians and heart teams to make decisions regarding the timing of PCI in patients undergoing TAVR.” Dr. Dhoble is a cardiologist at University of Texas Health Science Center at Houston, Texas.